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Abstract
Increasing infections with Monkeypox and Cowpox viruses pose a continuous and growing threat to human
health. The standard method for detecting poxvirus neutralizing antibodies is the plaque-reduction neutralization
test that is specific but also time-consuming and laborious. Therefore, a rapid and reliable method was developed
to determine neutralizing antibody titers within twelve hours. The new assay measures viral mRNA transcription as
a marker for actively replicating virus after incomplete neutralization using real-time PCR.
Background
The increasing number of humans infected with zoono-
tic orthopox viruses (OPV) such as Cowpox and Mon-
keypox virus poses a continuous and increasing threat
to human health [1]. Thus, efforts to develop new vac-
cines against OPV infections remain important. Natural
immune response and efficacy of vaccines are character-
ized through their capacity to induce neutralizing anti-
bodies. The standard diagnostic method to determine
OPV neutralizing antibodies in plasma or serum sam-
ples is the plaque-reduction neutralization test (PRNT).
It quantifies neutralizing antibodies by measuring the
reduction of virus-induced plaques where one infectious
virus particle is directly related to one virus-formed pla-
que. PRNT is the gold standard because it is specific,
direct and reproducible [2]. However the PRNT suffers
from long turn-around times (several days), is laborious
and uses an operator-error prone manual readout based
on calculating the neutralization titer from the number
of plaques counted. Due to long incubation times of the
infected cell cultures necessary to allow plaque forma-
tion, anti-co-agglutinants like EDTA and plasma compo-
nents can interfere with the cell monolayer and affect
plaque formation, especially in low plasma dilutions.
While pre-dilution of plasma might reduce these effects,
it also reduces sensitivity of the PRNT and low titers of
neutralizing antibodies might be missed.
Recently, four alternative methods were described to
determine neutralizing anti-Vacinia virus (VACV) anti-
bodies using either a beta-galactosidase expressing
VACV Western Reserve strain (WR) [3] or recombinant
GFP expressing VACV strains [4,5]. Eyal et al. [6] mea-
sured remaining infectivity by enzyme immunoassay
using VACV strains WR and Lister Elstree (LE). These
assays are designed for large-scale screening but still are
time consuming. Additionally, three of them require the
use of specific recombinant VACV strains.
The assay presented here uses VACV LE and human
VACV immunoglobulin (HIVIG) as a model system and
quantifies neutralizing anti-VACV antibodies by combin-
ing the classic PRNT with a OPV-specific real-time PCR
(designated NT-PCR) allowing quantification of replicat-
ing virus within a few hours after infection of the host cell.
Results and discussion
Validation of real-time PCR assays
To quantify actively replicating virus, three OPV-specific
reverse transcriptase real-time PCR assays were estab-
lished. The OPV12/13 a s s a yt a r g e t st h eg e n ef o rt h e
VACV LE DNA-binding phosphoprotein involved in
DNA replication and nucleotide metabolism. The other
two OPV-specific real-time PCR assays, D8L and Rpo18
[7], are specific for the D8L membrane protein coding
region of IMV particles and the 18-kDa RNA polymer-
ase subunit gene, respectively. All three real-time PCR
assays were OPV-specific, showed no cross-reactivity to
cellular genes (data not shown) and therefore were
used as a measure for replicating virus within cells.
To standardize virus mRNA copies to an equal number
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assay was used. All assays have a linear detection range
from 10
6 to 10 copies per reaction with an overall R
2 of
≥ 0.98 and PCR efficiencies ≥ 95% (table 1), which are
common features for many other real-time PCR assays
used in virology and microbiology [8-10]. Results of
intra- and inter-assay variability for plasmids standards
were less than 1 CT (see details for OPV12/13 and c-myc
assays in table 1) demonstrating a high degree of intra-
and inter-assay precision.
Evaluation of HVIG neutralizing antibody titers with
standard PRNT
Neutralizing antibody titers of HVIG (VIG and Omri-
gam) were first determined with the standard PRNT.
The PRNT titer is defined as the antibody dilution
resulting in 50% plaque reduction. HVIG preparations
were tested using 4.4 × 10
1 pfu/well VACV LE and 1 h,
2 h or 3 h of incubation for virus neutralization. For
both, VIG and Omrigam, the mean neutralizing PRNT
titer from three independent measurements was 1:320±
one dilution step. VIG neutralizing titers varied depend-
ing on neutralization time: 1:160 (n = 1/3 for 1 h neu-
tralization, n = 1/3 for 2 h neutralization), 1:320 (n = 2/
3 for 1 h, 2 h and 3 h neutralization) and 1:640 (n = 1/3
for 3 h neutralization). The PRNT titer for Omrigam
was always 1:320 (n = 3 for 1 h, 2 h and 3 h of neutrali-
zation). As both HVIG showed the same neutralizing
activity in the PRNT, VIG was used for establishment of
the NT-PCR assay for reason of availability.
The NT-PCR assay
The NT-PCR assay principle is based on measuring
actively replicating VACV LE by quantifying virus mRNA
levels in infected Vero E6 cells. Since cell numbers per
well, RNA integrity and quantity can vary all virus copy
numbers were normalized against 10
6 copies of the cellu-
lar reference gene transcript of c-myc. The c-myc gene is
expressed constitutively and independently from experi-
mental conditions and sample treatment, different cell
types and developmental stages. It is not affected by the
infection with different OPVs (A. Nitsche, personal com-
munication). After pre-incubation of VACV LE with VIG
fewer cells became infected compared to VACV LE alone
resulting in a decreased virus mRNA copy number due
to neutralization of infectious virus. For VACV LE incu-
bated with negative human serum virus mRNA copy
numbers were set to 100%. Based on the mRNA copy
numbers determined for each antibody dilution the per-
centage of replicating virus was calculated in comparison
to the 100% expression in virus control sample.
For the NT-PCR assay virus concentrations of 4.4 ×
10
1,2 . 2×1 0
2 and 4.4 × 10
2 pfu/well were tested using
experimental conditions similar to the standard PRNT
with 1 h neutralization time and 24 h for infection and
replication in order to compare both assays. Using 4.4 ×
10
1 and 2.2 × 10
2 pfu/well of VACV LE, levels of viral
mRNA were below detection threshold of the OPV12/13
real-time PCR assay (< 10
1 copies) for antibody dilutions
1:40-1:80. For antibody dilutions ≥ 1:160 copy numbers
varied between 10
1 and 10
3 copies. No correlation
between virus replication and antibody dilution was
observed. In contrast, when using a virus dose of 4.4 ×
10
2 pfu/well, ≥ 10
1 OPV12/13 copies were detected for all
antibody dilutions tested. A significant increase of virus
replication could be detected for an antibody dilution of
≥ 1:640. Therefore, an infectious dose of 4.4 × 10
2 pfu
was selected for further experiments.
Table 1 Variability and efficiency of OPV12/13 and c-myc real-time PCR assays
PCR Assay copy no. Variability* CT R
2 ** PCR Efficiency
(%) **
intra-assay inter-assay
OPV 12/13 10
6 17.58 ± 0.23 17.42 ± 0.20 0.99 96.00
10
5 20.33 ± 0.16 20.55 ± 0.20
10
4 24.13 ± 0.15 24.34 ± 0.21
10
3 27.01 ± 0.08 27.42 ± 0.41
10
2 31.22 ± 0.08 31.24 ± 0.38
10
1 34.42 ± 0.05 34.96 ± 0.47
c-myc 10
6 19.63 ± 0.04 19.74 ± 0.46 0.99 97.62
10
5 23.23 ± 0.28 23.09 ± 0.31
10
4 26.40 ± 0.05 26.61 ± 0.29
10
3 29.53 ± 0.02 29.65 ± 0.55
10
2 34.73 ± 0.49 33.76 ± 0.97
10
1 36.74 ± 0.36 36.39 ± 0.58
* for the determination of the intra-assay variability, plasmid standards (10
6-10
1 plasmid copies) were measured in triplicate, and for the inter-assay variability,
measurements were repeated on 3 consecutive days; ** calculation using the slope of the calibration curves for plasmid standards (10
1-10
6 plasmid copies); The
linear detection range is 10
6-10
1 copies per run. CT threshold cycle.
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evaluated after 1 h, 2 h and 3 h of co-incubation of
VACV LE with the VIG antibodies. For 1 h and 3 h of
co-incubation no significant correlation was detected
due to high variability of virus replication for all anti-
body dilutions. After 2 h a significant increase of virus
replication was observed correlating with increasing
antibody dilution. Virus mRNA copy numbers revealed
≤ 3x10
2 OPV12/13 copies for antibody dilutions < 1:640
whereas copy numbers for dilutions ≥ 1:640 increased at
least twofold (data not shown). A visual cut-off was set
for a dilution of 1:640 and neutralization time of 2 h
was chosen for further validation.
While a complete replication cycle of OPV takes
between 9 and 24 h [11,12], early gene expression is
detectable by real-time PCR less than 30 min after infec-
tion [13]. In initial experiments virus was allowed to
replicate for 24 h to ensure one complete replication
cycle. However, to reduce assay time, expression of viral
genes was evaluated after 5 h and 7 h of virus infection.
Additionally to the OPV12/13 assay, two other real-time
PCR assays (Rpo18, D8L) were tested simultaneously.
While all three assays target genes highly conserved
between OPV species only OPV12/13 and Rpo18 target
genes directly involved in virus replication. Although all
tested OPV-specific real-time PCR assays have similar
characteristics in terms of sensitivity, amplification effi-
ciency and specificity no significant correlation between
antibody dilution and virus neutralization could be seen
with the D8L real-time PCR assay (data not shown).
Thus, the D8L assay was not used for further experi-
ments. In contrast, after 7 h but not after 5 h of virus
replication, the Rpo18 and OPV12/13 real-time PCR
assays were successfully and consistently detecting
increased viral mRNA levels for antibody dilutions ≥
1:1280 and 1:640, respectively, indicating reduced virus
neutralization. Using the OPV12/13 and Rpo18 assay a
significant correlation bet w e e na n t i b o d yd i l u t i o na n d
virus replication was detected. The results for OPV12/13
a n dR p o1 8s u g g e s tt h a ti ti si m p o r t a n tt ou s ear e a l -
time PCR that targets a gene directly involved in virus
replication. As the OPV12/13 assay was originally
designed to detect the DNA binding phosphoprotein of
VACV the OPV12/13 and an infection time of 7 h was
selected for further validation of the NT-PCR.
To ensure a qualitative and repetitive readout, the
neutralizing antibody titer (= NT-PCR titer) was calcu-
lated based on a plot of the antibody dilution versus
percentage of virus replication: the point at which the
curve becomes near-horizontally (the slope approaches a
near-zero value) defines the NT-PCR titer (Figure 1).
This point is characterized by incomplete virus neutrali-
zation with significant increase in virus replication as a
result of antibody dilution. Mathematically this point
can be identified by defining the titration curve as a
combination of two linear segments (lower than dilution
x (segment a) and higher than dilution x (segment b))
and using linear regression to identify the intersection
(dilution x) that leads to the best fits on both segments:
The intersection (dilution x), that results in the best lin-
ear fit (R2) on both modeled linear segments (= highest
R2a+R2b), defines the NT-PCR titer.
Intra-assay variation of the NT-PCR was determined
based on four runs performed in parallel. To evaluate
inter-assay variability the NT-PCR assay was performed
on four different days. Calculation of the NT-PCR titer
was performed for a total of seven assays (table 2). The
NT-PCR is designed as a single well format assay and
measures the inhibition of virus replication for a parti-
cular antibody dilution in one well. However, to
decrease the variability between samples on the same
plate the actual NT-PCR titer was calculated using the
means of % virus replication of either two (for 5 out of
7 assays), three (for 1 out of 7 assays) or four (for 1 out
of 7 assays) single wells which were set up in parallel
and treated identically. Comparison of the cut-off values
(= NT-PCR titer) resulted in an intra- and inter-assay
variability of 1:640 ± one dilution step (table 2, Figure 2)
independent of the number of single wells used to calcu-
late the mean value. Statistical analysis indicates that
dilutions from 1:40 to 1:640 where not significantly dif-
ferent to each other. However, all individual dilutions
between 1:40 and 1:640 are significantly different to dilu-
tions ≥ 1:640. This further shows that the introduction of
aq u a n t i t a t i v eP C Ra l l o w st h e reliable calculation of a
neutralizing antibody titer that is not exclusively based
on a visual readout as in the case of the PRNT assay
which might be subject to operator error.
To explore the NT-PCR assay’s application for clinical
use, serum samples of six individuals recently vaccinated
with VACV LE were tested using both, PRNT and NT-
PCR. As only small serum volumes were available, serial
dilution of serum was started at 1:40. For two of the six
serum samples the outcome was identical in both tests
(table 3). However, the NT-PCR and PRNT titers for three
serum samples differed between one and two dilution
steps still in the range of normal cell culture assay variabil-
ity. Patient sample no. 6 was considered to be an outlier,
as neutralizing antibody titers determined with both assays
could not be confirmed due to lack of sample volume.
Neutralizing titers are not identical as both assays have a
different readout and definition of the cut-off of the titer.
Moreover, the limited number and small sample volumes
of sera available prevented further evaluation of the NT-
PCR assay as well as statistical comparison.
Although further evaluation with clinical samples is
needed this preliminary evaluation indicates that it will
be suitable for routine diagnostic use especially if results
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Page 3 of 7are needed rapidly, if plasma components interfere with
the cell culture or if neutralizing antibodies to viruses
with no or poor cytopathic effect in cell culture (no
need for the detection of plaques) need to be analyzed.
It should be easily adaptable to other DNA viruses as
soon as a suitable real-time PCR assay is available to
detect viral mRNA. For DNA viruses the detection of
viral mRNA indicates the presence of actively replicating
virus in the cell limiting the potential effect of contami-
nating DNA from the genome of the inoculated virus
just sticking to the cell surface. Also, the assay should
be adaptable to RNA viruses if active virus replication
could be determined and distinguished from mere con-
tamination from viral genomic RNA. Assay conditions
need to be adapted for each new virus, however, this is
also true for standard PRNT assays.
Taken together, the new and rapid NT-PCR assay can
be completed within 12 h while the turn-around time of
the standard PRNT is at least 4 days. Final NT-PCR
conditions are: 4.4 × 10
2 pfu/well VACV LE, 2 h of neu-
tralization time, 7 h of infection and replication time
and final quantitative examination of virus mRNA
copies in cells by quantitative OPV12/13 real-time PCR.
Conclusions
The NT-PCR assay is a fast, reliable and sensitive tool
for the detection of VACV neutralizing antibodies. It
will be suitable for routine diagnostic and could pose a
valuable alternative to the standard PRNT assay. The
low detection limit and the high degree of accuracy for
the detection of replicating virus by real-time PCR
resulted in high reproducibility and short assay turn-
around time. This assay can be performed with all wild-
type OPV strains without the need of particular VACV
reporter strains. It may also be beneficial for viruses
with no or poor cytopathic effect in cell culture.
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Figure 1 Graphical illustration of deriving the NT-PCR neutralizing titer in a normal analytical setting. Instead of performing statistical
analysis of multiple runs (as in figure 2) the point at which the slope of the curve shows a sudden decrease to a near-zero value identifies the
point of significant increase of virus replication caused by incomplete virus neutralization (if antibody dilution is plotted against percent virus
replication) and defines the neutralizing antibody titer. Mathematically, this point can be derived by treating the curve as a composition of two
near-linear fragments (colored curves). The intersection (arrows in enlarged insert), which results in the best linear fit (R2) on both modeled linear
segments (= highest R2a+R2b) defines the NT-PCR titer. Numbers indicate curves derived from different number of replicates per run: #1 and #2:
mean values of two wells; #3: mean value of three wells; #4: mean value of four wells analyzed per dilution step, respectively. Independent of
the number of replicates analyzed the resulting neutralization titer was always the same, suggesting that duplicate measurements should suffice
for normal clinical or analytical application of the NT-PCR assay.
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Cells, viruses and antibodies
VACV LE was propagated in Hep2 cells (ECACC:
86030501). Vero E6 cells (ECACC: 85020205) were used
for virus stock titrations, for standard PRNT and NT-
PCR. Overlay medium was 1.6% carboxymethylcellulose
(CMC). All cells were maintained according to ECACC
recommendations.
VACV LE (Bavarian Nordic, Martinsried, Germany)
(4.4 × 10
8 pfu/mL), human Vaccinia virus immunoglo-
bulin (HVIG) (VIG antibodies, BER/FDA Bethesda, MD,
USA and Omrigam 5%, G2H50CN HO4021, Israel,
2003) and sera from six individuals vaccinated with
VACV LE were used. All sera were tested for absence of
cytotoxicity.
PRNT
For standard PRNT 8.5 × 10
4 cells/well of Vero E6 cells
were seeded into 48-well plates and incubated over night.
HVIG and sera were twofold serially diluted in cell cul-
ture medium from 1:40 to 1:2560 and mixed with an
equal volume of VACV LE to 4.4 × 10
1 pfu/100 μL.
Medium served as negative control. After 1 h 100 μLo f
serum-virus mixture was added to cells in 100 μL cell
culture medium. Plates were centrifuged (15 min, 200 ×
g) and virus was allowed to adsorb for 1 h at 37°C. Next,
cells were overlaid with 400 μL overlay medium and
Table 2 Calculation of the neutralizing antibody titer determined with NT-PCR assay (1.) and its intra- and inter-assay
variability (2.)
1. Calculation of the NT-PCR assay
Σ R
2 single well*
antibody dilution assay # 1
a 2
a 3
a 4
a 5
a 6
b 7
c
1:40 0.0250 0.25 0.31 0.27 0.33 0.22 0.32 0.31
1:80 0.0125 1.34 1.37 1.31 1.37 1.26 1.35 1.42
1:160 0.0063 1.44 1.36 1.28 1.27 1.30 1.23 0.71
1:320 0.0031 1.61 1.52 1.45 1.49 1.17 1.44 1.11
1:640 0.0016 1.20 1.77 1.65 1.73 1.41 1.65 1.43
1:1280 0.0008 1.23 1.34 1.30 1.54 1.30 1.41 1.06
1:2560 0.0004 1.24 1.36 1.39 1.38 1.31 1.46 1.26
1:5120 0.0002 0.25 0.31 0.27 0.33 0.22 0.32 0.31
2. Inter-and intra-assay precision
respective NT-PCR titer for each assay
day 1 day 2 day 3 day 4 inter-assay variability
assay 1 1:320 assay 3 1:640 assay 4 1:640 assay 5 1:640 1:640± one dilution
assay 2 1:640
assay 6 1:640
assay 7 1:640
intra-assay variability 1:640± one dilution
*R
2 is the R-squared value (R-squared value is the fraction of the variance in the data that is explained by a regression); ΣR
2 is the sum of R1
2 and R2
2; single
well sample 1-7:
a mean value resulting from two wells;
b mean value resulting from three wells;
c mean value resulting from four wells; NT-PCR antibody titer is
highlighted in bold and underlined and corresponds to the highest ΣR
2.
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Figure 2 Determination of neutralizing antibody titer as
established using the NT-PCR. Percent virus replication is plotted
against antibody dilution and the neutralizing titer is defined by the
last antibody dilution step before virus replication is significantly
increasing (≥1:640). Data is shown for seven individual runs using
mean values from two, three and four single wells. Bars indicate
means and SD, as a normal distribution of the repeated measures
was assumed. The p-value indicates significant differences across all
compared dilution groups (significance indicated by *): # the grey
dotted line indicates the range of dilutions from 1:40 to 1:640
where no significant differences between the individual dilution
steps are observed, however all individual columns are significantly
different to dilutions ≥ 1:640 (1:1280 or higher).
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Page 5 of 7incubated for 4 days. Medium was aspirated and cells
were fixed with 4% formaldehyde for 30 min, stained
with naphthalen blue black and washed once with tap
water. Plaques were counted and the titer for 50% plaque
reduction was calculated referred to VACV-negative
serum.
NT-PCR assay
To optimize the NT-PCR assay, three VACV LE concen-
trations (4.4 × 10
2,2 . 2×1 0
2 and 4.4 × 10
1 pfu/well), a
neutralization time between 1 h, 2 h and 3 h, total incu-
bation time for virus entry and initial replication of 24 h,
7 h or 5 h and three different viral target sequences for
OPV-specific real-time PCR were investigated. All other
preceding steps were performed according to the stan-
dard PRNT. After incubation, medium was aspirated and
cells were washed with PBS, trypsinized, washed twice
with PBS and centrifuged (5 min, 250 × g). Cell pellet
was immediately resuspended in 700 μLR L Tb u f f e ra n d
RNA was extracted using the RNeasy Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s proto-
col. Residual DNA was eliminated by DNase treatment
(Turbo DNase Kit; Ambion, Hamburg, Germany). cDNA
was synthesized in a total volume of 20 μLc o n t a i n i n g
500 ng Oligo dT(18) primer, 500 ng calf thymus DNA and
10 μL RNA. No RNase inhibitors were added as all RNA
samples were processed immediately after extraction.
After 5 min at 65°C a mix consisting of 4 μL 5 × buffer, 2
μL 0.1 M DTT, 0.4 μL2 5m Md N T Pa n d2 0 0US u p e r -
script II reverse transcriptase (Invitrogen, Karlsruhe, Ger-
many) was added.
Samples were incubated at 37°C for 50 min and at 70°C
for 15 min. For each RNA sample a reverse transcription
(RT) control reaction was performed replacing the
reverse transcriptase water to verify absence of contami-
nating DNA. Quality of cDNAs was tested using the c-
myc real-time PCR assay which simultaneously served as
control of RNA extraction and cDNA synthesis. Only
cDNA with CT values ≥ 10
4 c-myc copies per reaction
were further analyzed. Four real-time PCR assays target-
ing different viral genes (table 4) were established and
tested to quantify VACV gene expression as indicator for
active virus replication. The respective amplicons of all
real-time PCRs were cloned into pCR2.1 vector, accord-
ing to the manufacturer’si n s t r u c t i o n s( T O P OT AC l o n -
ing Kit, Invitrogen, Karlsruhe, Germany). Plasmids were
purified, copy numbers calculated and tenfold serially
diluted in a background of 1 ng/μL l DNA (Fermentas,
St. Leon-Rot, Germany). Samples were measured in
Table 3 Serum samples from VACV LE vaccinated
individuals analyzed by PRNT and NT-PCR
Patient #* NT-PCR titer PRNT titer
1 1:80 1:40
2 1:160 1:40
3 1:160 1:160
4 1:320 1:640
5 1:40 1:40
6
§ 1:640 1:40
* lowest dilution step was 1:40, bigger volumes of serum were not available.
§ result for this patient is considered as outlier (PRNT was done only once
because of lack of serum availability).
Table 4 Details of oligo nucleotides used in PCR reactions
Oligo name Oligonucleotide sequence 5’®3’ S/A Ta (°C) Tm (°C)
c-myc 60.0
c-myc F GCCAGAGGAGGAACGAGCT S 59.4
c-myc R GGGCCTTTTCATTGTTTTCCA A 54.2
c-myc TM F-TGCCCTGCGTGACCAGATCC-T S 65.9
OPV12/13/MPXV
82 protein
62.0
OPV F GCCAATTGTCTTTCTCTTTTACTGA S 56.2
OPV R GAAAACATTTAAGGATGAATCCATCT A 55.4
OPV TMGB F-CCTTCTATAGATCTGAGAAT NQF MGB S 65.5
rpo18/polymerase
# 60.0
rpo18 F CTGTAGTTATAAACGTTCCGTGTG S 50.7
rpo 18 R TTATCATACGCATTACCATTTCGA A 47.0
rpo18 TM F-ATCGCTAAATGATACAGTACCCGAAXTCTCTACT-PH
D8L/IMV membrane protein 60.0
D8L F GGATGTTCTATATACGGGGATGAGTAG S 57.9
D8L R AAAGTTAATAAGGTAGATGACACGTTCT A 58.5
D8L TM F-TTCTCATCATCAGAATAAA-NFQ MGB S 65.1
Y = C or T, B = C or G or T, W = A or T, F = FAM label, T = TAMRA label, TM = hydrolysis probe, TMGB = hydrolysis probe coupled to an MGB moiety;
MGB = Minor Groove Binder, NFQ = Non-fluorescent quencher, Tm = Melting temperature (calculated by nearest neighbor method), Ta = Annealing temperature,
A = antisense orientation, S = sense orientation, # [7].
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copy numbers using 7900 and 7500 real-time PCR instru-
ments (Applied Biosystems, Darmstadt, Germany). The
25 μL reaction volume included 2 μL cDNA or plasmid
DNA, 2.5 μL1 0×b u f f e r ,2 . 0μLM g C l 2 (50 mM), 1 μL
dNTP (25 mM each), 0.75 μL of forward and reverse pri-
mers (10 μM), 0.25 μL probe (10 μM), 0.25 μL ROX (100
mM), 1 U Platinum Taq polymerase (Invitrogen, Karls-
ruhe, Germany) and 15.3 μL water. Cycling conditions
were 2 min at 50°C, 10 min at 95°C, followed by 45 cycles
of 15 sec at 95°C and 30 sec at 60°C (62°C, OPV12/13).
Statistical analyses were done using GraphPad’sP r i s m
software (Version 5.0a) and a repeated measures
ANOVA test and “Tukey’s Multiple Comparison Test”
was used for statistical analysis and p-value ≤ 0.05 was
regarded as significant.
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